Paul J. Lytle
2014
In 2014, Paul J. Lytle earned a total compensation of $844K as Chief Financial Officer at Peregrine Pharmaceuticals, a 7% increase compared to previous year.
Compensation breakdown
| Bonus | $84,711 |
|---|---|
| Non-Equity Incentive Plan | $146,381 |
| Option Awards | $236,280 |
| Salary | $338,844 |
| Other | $37,811 |
| Total | $844,027 |
Lytle received $338.8K in salary, accounting for 40% of the total pay in 2014.
Lytle also received $84.7K in bonus, $146.4K in non-equity incentive plan, $236.3K in option awards and $37.8K in other compensation.
Rankings
In 2014, Paul J. Lytle's compensation ranked 8,302nd out of 13,032 executives tracked by ExecPay. In other words, Lytle earned more than 36.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,302 out of 13,032 | 36th |
Division Manufacturing | 3,081 out of 4,966 | 38th |
Major group Chemicals And Allied Products | 1,043 out of 1,686 | 38th |
Industry group Drugs | 822 out of 1,365 | 40th |
Industry Pharmaceutical Preparations | 637 out of 1,043 | 39th |
Source: SEC filing on August 28, 2014.
Lytle's colleagues
We found five more compensation records of executives who worked with Paul J. Lytle at Peregrine Pharmaceuticals in 2014.
2014
Steven King
Peregrine Pharmaceuticals
Chief Executive Officer
2014
Jeffrey Masten
Peregrine Pharmaceuticals
Former Vice President, Quality
2014
Mark Ziebell
Peregrine Pharmaceuticals
General Counsel
2014
Shelley Fussey
Peregrine Pharmaceuticals
Vice President, Intellectual Property
2014
Joseph Shan
Peregrine Pharmaceuticals